Observational Study in Patients Suffering From Benign Prostatic Hyperplasia Treated With Alpha-adrenergic Blockade
Completed
- Conditions
- Prostatic Hyperplasia
- Interventions
- Drug: alpha-adrenergic blocker
- Registration Number
- NCT02244307
- Lead Sponsor
- Boehringer Ingelheim
- Brief Summary
The primary objective of this observational study was the assessment of prognosis factors for having recourse to prostatic surgery in patients with BPH who were administered class-1 alpha blockers. The secondary objectives were the assessment of the time from alpha-adrenergic blockade treatment initiation to surgery and the evolution of patients during the study.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Male
- Target Recruitment
- 4561
Inclusion Criteria
- Any patient with BPH for whom alpha-blocker treatment is indicated
- Patients who are already on class-1 alpha-blockers can only participate in the study if all information required is known and/or available
Read More
Exclusion Criteria
- Patient's follow-up not possible
- Patients participating in another study
- History of BPH surgery
- Prostate cancer
Read More
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Patients with BPH treated with alpha-andrenergic blockade alpha-adrenergic blocker -
- Primary Outcome Measures
Name Time Method Assessment of prognosis factors for having recourse to prostatic surgery up to 2 years
- Secondary Outcome Measures
Name Time Method Time form alpha-adrenergic blockade treatment initiation to surgery up to 2 years Occurrence of concomitant BPH diseases up to 2 years Percentage of patients with ongoing BPH treatment up to 2 years Total International Prostate Symptom Score (IPSS) up to 2 years